Relay Therapeutics (RLAY) Current Leases (2019 - 2026)

Relay Therapeutics (RLAY) has reported Current Leases for 8 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 34.44% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (down 34.44% YoY), while the FY2025 annual figure was $3.8 million, down 34.26% from the prior year.
• Current Leases climbed to $3.9 million in Q1 2026 per RLAY's latest filing, from $3.8 million in the prior quarter.
• Across five years, Current Leases topped out at $5.9 million in Q1 2025 and bottomed at $1.9 million in Q1 2022.
• Historically, Current Leases has averaged $4.4 million across 5 years, with a median of $4.6 million in 2023.
• Annual changes were most pronounced in 2022 — Current Leases surged 221.32% — and 2026, when it tumbled 34.44%.
• Relay Therapeutics' Current Leases stood at $4.3 million in 2022, then gained by 16.09% to $5.0 million in 2023, then gained by 15.37% to $5.7 million in 2024, then tumbled by 34.26% to $3.8 million in 2025, then advanced by 3.27% to $3.9 million in 2026.
• Business Quant data shows RLAY's Current Leases at $3.9 million in Q1 2026, $3.8 million in Q4 2025, and $3.6 million in Q3 2025.